Hikal Limited shareholders approved the appointment of Sameer Hiremath as Chairman and Managing Director for a five-year term starting October 1, 2026. The decision was taken during the company's 38th Annual General Meeting held on September 23, 2026.

The meeting also ratified a total dividend of ₹0.60 per equity share for FY26. The appointment of Hiremath, effective from October 1, 2026, to September 30, 2031, received majority support despite institutional reservations. Shareholders also approved audited standalone and consolidated financial statements for the year ended March 31, 2026, along with the re-appointment of Sarangan Suresh as Executive Director.

Leadership continuity and remuneration

Sameer Hiremath has been associated with Hikal's Board since May 1999 and was last reappointed as Managing Director at the 2021 Annual General Meeting. His continued leadership spans almost three decades, during which Hikal expanded capabilities across pharmaceuticals, crop protection, and emerging life-sciences businesses.

Shareholders approved the revision in remuneration for Sarangan Suresh, Whole-Time Director, who was re-appointed following retirement by rotation. Additionally, the ratification of remuneration payable to Cost Auditors for FY27 was approved.

Voting results breakdown

The voting data reveals distinct patterns in shareholder support. While institutional investors showed strong alignment on financial matters, promoter group votes were split on several governance-related items.

What the numbers show

A significant divergence exists between promoter and public voting behavior regarding leadership appointments. For the appointment of Sameer Hiremath as CMD, promoters voted nearly evenly (50.59% in favour vs 49.40% against), while public institutions voted predominantly against (56.58% against). In contrast, non-institutional public shareholders voted overwhelmingly in favour (90.69%). This suggests that while retail investors supported the leadership continuity, institutional investors expressed reservations regarding the specific terms or appointment, which was narrowly overcome by the combined weight of promoter and retail votes.

Strategic expansion and sustainability

Hikal recently commenced commercial production of Personal Care products at its new cGMP-compliant multipurpose facility at Panoli, Gujarat. This facility marks Hikal's entry into commercial-scale manufacturing for the global beauty and personal care industry. The company also announced it has been awarded the EcoVadis Gold Medal rating, placing it among the top 5% of companies assessed globally for sustainability performance.

Hikal Limited has announced the commencement of commercial production for its personal care products at a new cGMP-compliant facility in Panoli, Gujarat. The milestone on September 22, 2026, marks the company's formal entry into commercial-scale supply for the global beauty and personal care industry.

The new multipurpose facility was created by repurposing an existing manufacturing asset to meet the specific regulatory and quality standards of the beauty sector. Hikal leveraged its decades of experience in process chemistry and regulatory manufacturing to transition this capability into a new customer base. The facility has already manufactured its first production batches, with product samples validated by customers receiving positive feedback that indicates strong initial market pull.

Strategic focus on skincare ingredients

Hikal's initial strategy within the personal care segment targets the skin care category, where global demand is accelerating. The company has developed a portfolio focused on second-generation UV filters, designed to offer enhanced performance and align with tightening regulatory requirements in key international markets. These products are currently undergoing approval processes with global customers, representing a diversification beyond Hikal's core pharmaceuticals and crop protection businesses.

Sameer Hiremath, Vice Chairman and Managing Director, stated that the commissioning of the Panoli facility and the subsequent customer validation reflect a disciplined approach similar to that used in building their established segments. He noted that the combination of deep customer partnerships, rigorous quality systems, and patient capital investment positions the business for growth in the coming years.

Capability expansion and sustainability

This development is part of a broader pattern of capability building across Hikal's platform. Recently, the company also commissioned a new cGMP pilot plant at its Pune Research & Technology campus. This facility is intended to strengthen pharmaceutical process development and scale-up capabilities, supporting the growth of its CDMO (Contract Development and Manufacturing Organization) business.

The announcement follows Hikal's receipt of an EcoVadis Gold Medal rating for sustainability excellence. The company achieved an overall score of 84/100, placing it in the 97th percentile among more than 175,000 companies assessed globally. This recognition underscores Hikal's commitment to responsible manufacturing and sustainable procurement across its operations.

What the numbers show

The EcoVadis score of 84/100 and the 97th percentile ranking provide a quantifiable metric of Hikal's operational compliance and sustainability standing relative to its global peers. While the source does not disclose revenue figures for the new segment, the explicit linkage of the Panoli facility's output to "second-generation UV filters" highlights a strategic pivot toward high-value specialty ingredients rather than commodity chemicals. This aligns with the company's existing strength in regulated markets, suggesting that the new revenue stream will likely depend on successful regulatory approvals from global customers rather than immediate volume sales.